EnVivo Pharmaceuticals Inc.
This article was originally published in Start Up
The executives of EnVivo Pharmaceuticals Inc. believe they've assembled a discovery platform that will identify good drug candidates for Alzheimer's disease (AD) and other neurological disorders. The start-up's plan hinges on the ability to insert human genes known to underlie AD into the fruit fly Drosophila, and to use these model organisms to screen for compounds that can ameliorate the condition. EnVivo has an automated way of monitoring flies that develop symptoms that management believes are pertinent to AD in humans.
You may also be interested in...
Four start-ups previously profiled in START-UP – CoMentis, EnVivo Pharmaceuticals, Avid Radiopharmaceuticals and AC Immune SA – show how some biotechs have successfully ridden through the rough patches any company brave enough to tackle Alzheimer’s disease will likely face.
Fresh insights and tools are empowering start-ups pursuing treatments for Alzheimer's disease.
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.